II. Mechanism
- Protease-Activated Receptor-1 Antagonist (PAR-1 Antagonist)
- Inhibits Platelet aggregation for 4 weeks after dose
III. Indications
- Not intended to be used alone
- Limited to patients with very high cardiovascular risk
- Adjunctive therapy to low dose Aspirin or Clopidogrel (Plavix)
IV. Contraindications
- Prior Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA)
- Vorapaxar is associated with an increase risk of Hemorrhagic CVA in patients with prior cerebrovascular events
- Combination with other antiplatelet agents (other than Aspirin or Clopidogrel)
- Has not been studied with Prasugrel (Effient) or Ticagrelor (Brilinta)
- Avoid with strong CYP3A4 inhibitors or strong CYP3A4 inducers
VI. Precautions
- Long half-life
- No antidote in the case of severe bleeding
VII. References
Images: Related links to external sites (from Bing)
Related Studies
| zontivity (on 8/17/2016 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ZONTIVITY 2.08 MG TABLET | $9.24 each | |
